Nimbus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nimbus Therapeutics, Inc.
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- Nimbus Discovery LLC